Infective endocarditis in obstructive hypertrophic cardiomyopathy: a case series and literature review

Zi-Wen Wu, Hui Yan
Department of Cardiology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310000, China.

To the Editor: Infective endocarditis (IE) is a rare complication of hypertrophic cardiomyopathy (HCM) that may lead to fatal outcomes if the infection is not effectively controlled. We report three cases of hypertrophic obstructive cardiomyopathy (HOCM) complicated with IE, two of which were successfully treated by mitral valve replacement (MVR) and septal myectomy (SM) due to the presence of multiple branches of the septal artery and high surgical risk.

The first case was a 42-year-old woman presenting with low-grade fever, chest distress, shortness of breath, and worsening edema for 1 month. She had undergone cosmetic surgery (fat filling) 2 months prior. HOCM had been diagnosed for several years but she did not receive alcohol septal ablation or myomectomy due to the presence of multiple branches of the first septal artery and high surgical risk. So, she had been treated with an oral beta-blocker. A set of two blood cultures grew Gram-positive streptococci sensitive to linezolid, penicillin, ceftriaxone, and vancomycin on the third day after admission. Due to penicillin allergy, bacteremia was uncontrollable and complicated with IE. Subsequent echocardiography revealed severe mitral regurgitation with multiple patchy and echodense vegetations attaching to anterior and posterior mitral valve (MV) leaflet [Figure 1]. She underwent urgent MVR and SM due to worsening heart failure. Both the operation and postoperative pathology confirmed the formation of multiple vegetations in the MV. Her symptoms of heart failure were dramatically resolved after surgery and she was discharged after 25 days of parenteral treatment with amikacin and linezolid.

Our second case involved a 34-year-old woman complaining of worsening chest stuffiness, dyspnea on exertion, and low-grade fever for 10 days. She had been previously diagnosed with HOCM during a routine examination without receiving specific treatment. Echocardiography found multiple hypoechoic masses adherent to anterior and posterior MV leaflets, the largest of which was up to 2.0 cm × 1.3 cm in size. Blood cultures were sterile as she had already received short courses of antibiotics before admission. Albeit treated with empiric antibiotics, heart failure deteriorated, and the patient received MVR and SM. Abundant vegetations were seen in MV leaflets during surgery, leading to anterior MV leaflet perforation and severe mitral insufficiency. Fortunately, her symptoms were completely relieved after the operation and with improved observation, she was discharged.

The third case was an 86-year-old woman admitted for recurrent fever, chest stuffiness, and dyspnea on exertion for >1 month. She had symptoms of exertional dyspnea and chest discomfort for 10 years but was diagnosed as HOCM until 1 year ago. She received a dual-chamber pacemaker implanting for severe symptoms with regard to suboptimal clinical observation, she was discharged.

Spirito et al.[3] assessed the occurrence of IE in HOCM was 4.3% at 10 years and discerned an HCM subgroup with both obstruction and atrial dilatation prone to develop IE. Of the 640 IE patients in our hospital since 2009, only 3 (0.5%) were diagnosed as HCM. Consistent with the literature, these patients presented with both left outflow tract obstruction and atrial enlargement. However, recent studies of Dominguez et al.[2] and Sims et al.[3] showed a similar incidence of IE with or without obstruction in HCM. Nevertheless, the small sample size could be just a statistical outlier, limiting its universality. There is an urgent need for large retrospective and prospective studies.

Correspondence to: Dr. Hui Yan, Department of Cardiology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310000, China
E-Mail: michelleyan@zju.edu.cn

Copyright © 2020 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Chinese Medical Journal 2021;134(9)
Received: 21-04-2020 Edited by: Li-Shao Guo
to determine the true state of this population. Since intracardiac devices are increasingly implanted for HCM management in recent years, prophylactic antibiotic therapy should be taken into account for such patients at a high risk of bacteremia.

IE still carries high in-hospital mortality despite the diagnosis and treatment has greatly improved.

Numerous patients failing to respond to antibiotics still need to accept surgery because of uncontrollable sepsis, severe valvular regurgitation, or even recurrent embolic complications. Given the extensive mitral involvement of IE in general and the varying technical levels at each center, MVR is regarded as a more reasonable option for patients with older age, more comorbidities, decompensated heart failure, or uncontrolled sepsis and in patients who receive combined surgery. As we knew, SM may furnish a more complete remission of outflow tract gradients for refractory HOCM, as compared with percutaneous transluminal septal myocardial ablation.\textsuperscript{4} Although MVR and SM are exceedingly rare in most cases, the combined treatment is worthy of recommendation for IE patients with HOCM. Two of our patients who underwent MVR and SM both successfully gained relief of symptoms and improved functional class. A long-term study\textsuperscript{4} had shown that SM and MVR are safe procedures for symptomatic improvement and low mortality in 1–5 years postoperatively. Besides, MVR alone was correlated with a poorer outcome with less symptomatic benefit.

**Declaration of patient consent**

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patients have given their consent for their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

**Conflicts of interest**

None.

**References**

1. Spirito P, Rapezzi C, Bellone P, Betocchi S, Autore C, Conte MR, et al. Infective endocarditis in hypertrophic cardiomyopathy — Prevalence, incidence, and indications for antibiotic prophylaxis. Circulation 1999;99:2132–2137. doi: 10.1161/01.cir.99.16.2132.
2. Dominguez F, Ramos A, Bouza E, Munoz P, Valero MC, Carmen Farinas M, et al. Infective endocarditis in hypertrophic cardiomyopathy: a multicenter, prospective, cohort study. Medicine 2016;95:e4008. doi: 10.1097/md.0000000000004008.
3. Sims JR, Anavekar NS, Bhatia S, O’Horo JC, Geike JR, Chandrasekaran K, et al. Clinical, radiographic, and microbiologic features of infective endocarditis in patients with hypertrophic cardiomyopathy. Am J Cardiol 2018;121:480–484. doi: 10.1016/j.amjcard.2017.11.010.
4. Guo HC, Li JH, Jiang TY, Ren CW, Dai J, Zhou YJ, et al. Comparison of clinical effects between percutaneous transluminal septal myocardial ablation and modified morrow septal myectomy on patients with hypertrophic cardiomyopathy. Chin Med J 2018;131:527–531. doi: 10.4103/0366-6999.226075.
5. Collis R, Watkinson O, O’Mahony C, Guttmann OP, Pantazis A, Tome-Esteban M, et al. Long-term outcomes for different surgical strategies to treat left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. Eur J Heart Fail 2018;20:396–405. doi: 10.1002/ejhf.1038.

**How to cite this article:** Wu ZW, Yan H. Infective endocarditis in obstructive hypertrophic cardiomyopathy: a case series and literature review. Chin Med J 2021;134:1125–1126. doi: 10.1097/ CM9.0000000000001263